A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension

Trial Profile

A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TRANSFORM-UK
  • Most Recent Events

    • 29 Nov 2017 Planned End Date changed from 30 Sep 2017 to 30 Mar 2018.
    • 29 Nov 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top